Skip to main
SYBX
SYBX logo

Synlogic (SYBX) Stock Forecast & Price Target

Synlogic (SYBX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 8%

Bulls say

Synlogic Inc. operates in the biopharmaceutical sector, focusing on pioneering treatments for rare metabolic disorders, particularly phenylketonuria (PKU) and homocystinuria (HCU), using a proprietary platform that employs engineered probiotics. The company has a robust pipeline, including therapeutics for conditions such as enteric hyperoxaluria, gout, and cystinuria, which could potentially enhance its market position and financial metrics over time. With trading at approximately one-third of its cash reserves, Synlogic's current valuation may present an opportunity for future growth contingent on strategic decisions that can support its operational continuity and attract new investment.

Bears say

Synlogic Inc. reported a significant net loss of $14.5 million for the fourth quarter of 2023, equating to a loss of $1.71 per share, reflecting the company's financial struggles. The early termination of the Synpheny-3 trial due to efficacy futility has led to a drastic reduction in operations, including an over 90% workforce cut and the exit of key leadership, notably the CEO. These developments indicate substantial challenges in advancing Synlogic's pipeline and suggest a diminished capacity for future growth in the biopharmaceutical sector focused on rare metabolic disorders.

Synlogic (SYBX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Synlogic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Synlogic (SYBX) Forecast

Analysts have given Synlogic (SYBX) a Buy based on their latest research and market trends.

According to 13 analysts, Synlogic (SYBX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Synlogic (SYBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.